If you have been reading about size-exclusion HPLC and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-28. Numbers and descriptions here follow the published literature rather than marketing material.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilised powder | Visual inspection under suitable light |
| Aqueous solubility | Soluble, pH dependent | Dissolves readily in neutral buffer |
| Storage temperature | 2-8 °C short term; -20 °C or below long term | Protect from light and moisture |
| Primary purity method | Reversed-phase HPLC | UV detection near 214 nm |
| Identity confirmation | LC-MS with peptide mapping | Mass accuracy within a few ppm |
Stability studies focus on deamidation of asparagine and glutamine residues, oxidation of methionine, and aggregation into higher-order species. The fatty acid side chain adds susceptibility to oxidative change and can promote self-association at high concentration. Lyophilised material is comparatively robust when kept cold and dry, while aqueous solutions require refrigeration and protection from light. Forced degradation experiments under heat, acid, base, and peroxide conditions establish the specificity of each analytical method. Which degradation route dominates under real storage conditions depends on the formulation and stays formulation-specific.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
=== Immune system === The effect of estrogen on the immune system is in general described as Th2 favoring, rather than suppressive, as is the case of the effect of male sex hormone – testosterone. Indeed, women respond better to vaccines, infections and are generally less likely to develop cancer, the tradeoff of this is that they are more likely to develop an autoimmune disease. The Th2 shift manifests itself in a decrease of cellular immunity and increase in humoral immunity (antibody production) shifts it from cellular to humoral by downregulating cell-mediated immunity and enhancing Th2 immune response by stimulating IL-4 production and Th2 differentiation. Type 1 and type 17 immune responses are downregulated, likely to be at least partially due to IL-4, which inhibits Th1. Effect of estrogen on different immune cells' cell types is in line with its Th2 bias. Activity of basophils, eosinophils, M2 macrophages and is enhanced, whereas activity of NK cells is downregulated. Conventional dendritic cells are biased towards Th2 under the influence of estrogen, whereas plasmacytoid dendritic cells, key players in antiviral defence, have increased IFN-g secretion. Estrogen also influences B cells by increasing their survival, proliferation, differentiation and function, which corresponds with higher antibody and B cell count generally detected in women. On a molecular level estrogen induces the above-mentioned effects on cell via acting on intracellular receptors termed ER α and ER β, which upon ligation form either homo or heterodimers.
=== Stability of proteins from rates of oxidation (SPROX) === Stability of Proteins from Rates of Oxidation also rests upon the assumption that ligand binding confers protection to proteins from manners of degradation, this time from oxidation of methionine residues. In SPROX, a lysate is split and treated with drug or a DMSO control, then each group is further aliquoted into separate samples with increasing concentrations of the chaotrope and denaturant guanidinium hydrochloride (GuHCl). Depending on the concentration of GuHCl, proteins will unfold to varying degrees. Each sample is then reacted with hydrogen peroxide, which oxidizes methionine residues. Proteins that are stabilized by the drug will remain folded at higher concentrations of GuHCl and will experience less methionine oxidation. Oxidized methionine residues can be quantified via LC-MS/MS and used to generate methionine stability curves, which are a proxy for drug binding. There are drawbacks to the SPROX assay, namely that the only relevant peptides from SPROX samples are those with methionine residues, which account for approximately one-third of peptides, and for which there are currently no viable enrichment techniques. Only those methionines that are exposed to oxidation provide meaningful information, and not all differences in methionine oxidation are consistent with protein stabilization. Without enrichment, LC-MS/MS analysis of these peptides is challenging, as the contribution of other sample components to mass spectrometer noise can drown out relevant signal.
=== 2019 revision of the SI === The definition of the dalton was not affected by the 2019 revision of the SI, that is, 1 Da in the SI is still 1/12 of the mass of a carbon-12 atom, a quantity that must be determined experimentally in terms of SI units. However, the definition of a mole was changed to be the amount of substance consisting of exactly 6.02214076×1023 entities, and the definition of the kilogram was changed as well. As a consequence, the molar mass constant (Mu) remains close to but no longer exactly 1 g/mol, meaning that the mass in grams of one mole of any substance remains nearly but no longer exactly numerically equal to the average mass of an entity in daltons, although the relative standard uncertainty of 4.5×10−10 at the time of the redefinition is insignificant for all practical purposes. Letting ent denote one entity, the smallest amount of any substance (retaining its chemical properties), one mole is an aggregate of an Avogadro number of entities, i.e. 1 mol = N0 ent ≈ (g/Da) ent. This means that the appropriate atomic-scale unit for molar mass is dalton per entity (Da/ent), equal to the constant Mu, very nearly equal to 1 g/mol. For Da/ent to be exactly equal to g/mol, the dalton would need to be redefined exactly in terms of the (fixed-h) kilogram and the Avogadro number so that 1 Da = (1/N0) g, satisfying the relationships N0 = g/Da and 1 mol = N0 ent = (g/Da) ent, thus conforming to the original mole concept—that the Avogadro number is the gram-to-dalton mass unit ratio.
=== Pharmacodynamics === EcPLA has been found to interact with serotonin receptors and dopamine receptors, among other targets. It is a high potency agonist of the serotonin receptors, with its highest binding affinities at the 5-HT1A (Ki = 3.2 nM), 5-HT2B (Ki = 5.3 nM), and 5-HT5A (Ki = 8.6 nM) subtypes. Its 5-HT2A affinity is equivalent to that of LSD, while the affinity to 5-HT2C receptors is 3 times lower than LSD. It shares much of its binding profile with LSD, but does not bind to β1 or β2 adrenergic receptors as LSD does. The drug produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. It has about 40% of the potency of LSD in this regard.
{\displaystyle Q=\left[m_{\text{N}}\left({\ce {^{\mathit {A}}_{\mathit {Z}}X}}\right)+m_{\text{e}}-m_{\text{N}}\left({\ce {^{\mathit {A}}_{{\mathit {Z}}-1}X'}}\right)-m_{\nu _{\text{e}}}\right]c^{2},}
Sources: en.wikipedia.org
== Genitourinary and Gynecologic == Bladder cancer Cervical cancer Choriocarcinoma Embryonal carcinoma Endometrial cancer Endodermal sinus tumor Extragonadal germ cell tumor Fallopian tube cancer Gestational trophoblastic tumor Kidney cancer Leydig cell tumour Ovarian cancer Ovarian epithelial cancer (surface epithelial-stromal tumor) Ovarian germ cell tumor Penile cancer Prostate cancer Renal cell carcinoma Renal pelvis and ureter, transitional cell cancer* Seminoma Serous tumour Sertoli cell tumour Teratoma Testicular cancer Transitional cell cancer (urothelial carcinoma) Urethral cancer Uterine sarcoma Vaginal cancer Vulvar cancer Wilms tumor (nephroblastoma) Malignant Oncocytoma (Katie Coleman Tumor)
Past hypersensitivity or allergy to lorazepam, its ingredients in tablets or injections or any other benzodiazepine. Ataxia, a neurological clinical sign, consisting of unsteady and clumsy motion of the limbs and torso, due to the failure of gross muscle movement coordination, most evident on standing and walking. It is the classic way in which acute alcohol intoxication may affect a person. Benzodiazepines are not recommended to be administered to people who are already ataxic. Lorazepam has pupil-dilating effects, which may further interfere with the drainage of aqueous humor from the anterior chamber of the eye, thus worsening narrow-angle glaucoma. Sleep apnea may be worsened by lorazepam's central nervous system depressant effects. It may further reduce the person's ability to protect their airway during sleep. Myasthenia gravis, which is characterized by muscle weakness, may have exacerbated symptoms with muscle relaxants such as lorazepam. Lorazepam belongs to the Food and Drug Administration (FDA) pregnancy category D, which means it is likely to cause harm to the developing baby if taken during the first trimester of pregnancy. The evidence is inconclusive as to whether lorazepam if taken early in pregnancy results in reduced intelligence, neurodevelopmental problems, physical malformations in cardiac or facial structure, or other malformations in some newborns. Lorazepam given to pregnant women antenatally may cause floppy infant syndrome in the neonate, or respiratory depression necessitating ventilation.
Adding more of any of these intermediates to the mitochondrion therefore means that that additional amount is retained within the cycle, increasing all the other intermediates as one is converted into the other. Hence the addition of any one of them to the cycle has an anaplerotic effect, and its removal has a cataplerotic effect. These anaplerotic and cataplerotic reactions will, during the course of the cycle, increase or decrease the amount of oxaloacetate available to combine with acetyl-CoA to form citric acid. This in turn increases or decreases the rate of ATP production by the mitochondrion, and thus the availability of ATP to the cell. Acetyl-CoA, on the other hand, derived from pyruvate oxidation, or from the beta-oxidation of fatty acids, is the only fuel to enter the citric acid cycle. With each turn of the cycle one molecule of acetyl-CoA is consumed for every molecule of oxaloacetate present in the mitochondrial matrix, and is never regenerated. It is the oxidation of the acetate portion of acetyl-CoA that produces CO2 and water, with the energy thus released captured in the form of ATP. The three steps of beta-oxidation resemble the steps that occur in the production of oxaloacetate from succinate in the TCA cycle. Acyl-CoA is oxidized to trans-Enoyl-CoA while FAD is reduced to FADH2, which is similar to the oxidation of succinate to fumarate. Following, trans-enoyl-CoA is hydrated across the double bond to beta-hydroxyacyl-CoA, just like fumarate is hydrated to malate.
is a matrix, whose elements are so called influence coefficients relating the contact pressure and the deformation. The strict LCP formulation of the CM problem presented above, allows for direct application of well-established numerical solution techniques such as Lemke's pivoting algorithm. The Lemke algorithm has the advantage that it finds the numerically exact solution within a finite number of iterations. The MATLAB implementation presented by Almqvist et al. is one example that can be employed to solve the problem numerically. In addition, an example code for an LCP solution of a 2D linear elastic contact mechanics problem has also been made public at MATLAB file exchange by Almqvist et al.
Sources: en.wikipedia.org
Lower temperatures slow hydrolysis, oxidation and aggregation reactions that degrade the molecule over time. Lyophilised powder is more tolerant than solution, but both benefit from controlled conditions.
Mass spectrometry and peptide mapping are commonly used, often alongside chromatographic retention time comparison. No single technique covers both sequence and higher-order structure.
Aggregation is monitored because it can alter activity and may influence immune responses. Size-exclusion chromatography and related techniques are used to quantify it.
Manufacturers commonly state multi-year stability when the powder is kept dry and frozen. Actual shelf life depends on residual moisture, vial sealing, and storage temperature. A re-test by chromatography is the only way to confirm remaining purity.